Podcast: What is the urgency post-ACS to mitigate risk beyond the acute emergency, and whose job is it anyway?

Wednesday, 8 Jun 2022

Patients who survive an initial acute coronary syndrome (ACS) event are at high risk of further events, and real world evidence suggests that about one in five post-myocardial infarction patients goes on to have another cardiovascular events within a year. Despite this, only around one in two Australian patients are on high-dose statins for intensive lipid lowering therapy at 6 to 12 months after the initial event.

In this podcast, A/Prof Karam Kostner speaks to practicing clinicians about ways to improve post-ACS risk management.


A/Prof Karam Kostner is Director of Cardiology at Mater Hospital Brisbane and Associate Professor of Medicine at the University of Queensland. His guests are interventional cardiologist Dr James Shaw from the Melbourne Heart Group and Dr San San Min, a chemical pathologist in Woolongong and lipid specialist at the Cardiac Centre NSW.

Views and opinions expressed in this podcast are those of the presenter alone, and do not necessarily reflect the views and opinions of the sponsor. This information is not medical advice and no decision relating to the management of any patient should be made with reliance on the information contained in this podcast. It is your responsibility to prescribe appropriate treatments in accordance with your clinical judgment and by reference to the appropriate Australian Product Information or other information supplied with the relevant product, including in relation to any indication, dosage, and route of administration.

Praluent is an Authority-Required PBS listed product for Non-Familial and Heterozygous Familial Hypocholesterolaemia (refer to PBS schedule for further criteria and restrictions).


  1. Mach et al Eur Heart J 2020; 41(1): 111-188
  2. Ray KK et al. Eur J Prev Cardiol 2021; 28(11): 1279–1289
  3. Brieger D et al. Med J Aust 2019; 210 (2): 80-85
  4. Cannon et al. JAMA Cardiol 2021;6(9): 1060-1068
  5. Chew et al. Heart Lung Circ 2016; 25(9): 895-951
  6. Pharmaceutical Benefits Scheme
  7. Shaw W. Heart 2020;106(3): 172-173
  8. Simons LA et al.  Aust Fam Phys 2011;40:319-322

Already a member?

Login to keep reading.

Email me a login link

© 2022 the limbic